Roberto Ferrara, Medical Oncology Researcher at Vita-Salute San Raffaele University, shared a post on X about a recent article he and his colleagues co-authored, published in eClinicalMedicine:
” It is time to tailor 1st line treat in NSCLC according to primary/acquired ICI resistance.
Our reconstructed IPD analysis (19 RCTs) shows that adding platinum chemotherapy to ICI may increase acquired resistance (+15%) vs mono-ICI and decreased duration of response (5-7 mo).”
Title: Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis
Authors: Sara Oresti, Fabio Salomone, Antonio Nuccio, Francesca Rita Ogliari, Silvia Teresa Riva, Ludovica Mollica, Alessandra Bulotta, Maria Grazia Viganò, Francesco Maria Venanzi, Francesco Passaretti, Ludovica Papotto, Anna Di Lello, Michele Ferrara, Giorgia Foggetti, Giuseppe Damiano, Alberto Servetto, Raffaele Califano, Massimo Di Maio, Biagio Ricciuti, Alessio Cortellini, Roberto Ferrara
Read the Full Article on eClinicalMedicine
More posts featuring Roberto Ferrara.
